Form 8-K - Current report:
SEC Accession No. 0001628280-23-011672
Filing Date
2023-04-17
Accepted
2023-04-14 17:41:02
Documents
12
Period of Report
2023-04-14
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230414.htm   iXBRL 8-K 29142
  Complete submission text file 0001628280-23-011672.txt   158363

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230414.xsd EX-101.SCH 2011
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230414_lab.xml EX-101.LAB 24152
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230414_pre.xml EX-101.PRE 12609
6 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230414_htm.xml XML 4280
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 23822244
SIC: 2834 Pharmaceutical Preparations